To investigate the relationship between roflumilast and psychiatric adverse events (AEs) specifically linked to its use, utilizing the FDA Adverse Event Reporting System (FAERS) data.
Approach:
Key Findings:
414 reports of psychiatric AEs related to roflumilast were identified.
31 preferred terms for psychiatric AEs were noted.
Five significant positive signals were found: insomnia (ROR 3.55), suicidal ideation (ROR 4.32), sleep disorder due to a general medical condition (ROR 13.47), nervousness (ROR 3.30), and eating disorder (ROR 5.16).
Increased risk of life-threatening events and hospitalization associated with psychiatric AEs.
Interpretation:
The findings provide critical evidence for healthcare professionals to recognize and monitor psychiatric AEs associated with roflumilast, enhancing patient safety.
Limitations:
The study is based on post-marketing data, which may have reporting biases and underreporting.
The analysis does not establish causality between roflumilast and psychiatric AEs.
Conclusion:
The study highlights the urgent need for awareness and monitoring of psychiatric AEs associated with roflumilast in clinical practice to ensure patient safety.
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
